N GOLD stage III, buy Fexinidazole indicating that the mortality pattern followed the severity of airflow obstruction. By contrast, in Phenotype 3, mortality distributed among all GOLD stages (Figure 3). Kaplan-Meier analysis of mortality between the 3 phenotypes is presented in Figure 4. Subjects in Phenotype 2 and 3 were at higher risk of mortality than subjects in Phenotype 1 (each comparison, P,0.0001; log-rank test), but no significant differenceCOPD Phenotypes at High Risk of MortalityTable 2. Description of the 527 COPD patients based on phenotypes identified by cluster analysis.Phenotype 1 n = 219 DATA USED 22948146 IN THE CLUSTER ANALYSIS Quantitative data Age, yrs. BMI, kg/m2 12926553 FEV1, predicted Dyspnoea, mMRC scale Clinical COPD Questionnaire, Total TGV, predicted DLCO, predicted Categorical data CT scan* Emphysema present, Alveolar GSK -3203591 custom synthesis destruction Absent ( ) Mild ( ) Moderate ( ) Severe ( ) Bronchial thickening Mild ( ) Moderate ( ) Severe ( ) Bronchiectasis, Comorbidities Ischemic heart disease, Stroke, Peripheral arterial disease*, Diabetes, Muscle weakness*, Osteoporosis, Anaemia, 14 0 10 9 18 8 5 57 33 9 14 52 35 8 5 48 62 [58?8] 25 [23?8] 80 [65?4] 0 [0?] 1.8 [1.0?.0] 126 [112?47] 74 [60?6]Phenotype 2 n =Phenotype 3 n =P value61 [57?6] 20 [18?2] 29 [21?7] 2 [1?] 6.8 [5.0?.0] 195 [177?20] 34 [25?9]72 [65?7] 26 [24?9] 44 [36?8] 2 [2?] 6.3 [4.5?.0] 139 [115?61] 47 [38?1],0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.,0.4 9 4319 32 27,0.36 45 1920 52 27,0.,0.17 2 11 11 47 3134 8 19 20 42 22,0.001 ,0.001 0.08 0.003 ,0.001 ,0.001 0.DATA NOT USED IN THE CLUSTER ANALYSIS Male sex, GOLD stage G I, ( of all GOLD stage I) G II, ( of all GOLD stage II) G III, ( of all GOLD stage III) G IV, ( of all GOLD stage IV) Source of recruitment NELSON cohort, ( NELSON) LEUVEN clinic, ( LEUVEN) Smoking, pack-year FEV1, L FVC, predicted FVC, L FEV1/FVC ratio RV, predicted TLC, predicted Raw, predicted 67 (95) 33 (19) 44 [34?0] 2.4 [1.9?.9] 105 [92?18] 4.0 [3.3?.6] 0.62 [0.53?.67] 128 [109?49] 106 100?18] 174 [140?23] 0 (0) 100 (27) 48 [33?6] 0.8 [0.6?.0] 72 [61?6] 2.6 [1.9?.2] 0.33 [0.27?.38] 227 [186?68] 128 [116?39] 274 [215?79] 3 (5) 97 (54) 48 [31?5] 1.25 [1.0?.6] 82 [69?4] 2.8 [2.3?.3] 0.44 [0.37?.55] 144 [113?74] 104 [91?14] 249 [198?17] ,0.001 ,0.001 0.89 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 50 (91) 39 (51) 9 (13) 2 (5) 0 (0) 8 (5) 37 (25) 55 (61) 5 (9) 36 (44) 44 (62) 15 (35) 80 66 80 0.007 ,0.COPD Phenotypes at High Risk of MortalityTable 2. Cont.Phenotype 1 n = 219 Sgaw, predicted Kco, predicted Mortality, n ( ) 68 [51?7] 86 [71?8] 1 (0.5 )Phenotype 2 n = 99 29 [22?0] 53 [45?2] 20 (20.6 )Phenotype 3 n = 209 44 [32?4] 70 [56?1] 29 (14.3 )P value,0.001 ,0.001 ,0.* missing data: Phenotype 1:67 ; Phenotype 2:1 , Phenotype 3:4 . P values correspond to comparisons between the 3 phenotypes using Kruskal-Wallis or Chi-square tests, as appropriate. doi:10.1371/journal.pone.0051048.twere very similar to those identified in the French study [11]. Because all subjects had extensive characterization, including complete lung function assessment and CT scan, our current data further improve the description of these phenotypes. GarciaAymerich et al. also performed a cluster analysis of 342 Spanish subjects hospitalized 
for the first time because of COPD exacerbation [12]. The authors described 3 phenotypes, including “a severe respiratory phenotype” and “a systemic COPD phenotype” [12], which were at high risk of s.N GOLD stage III, indicating that the mortality pattern followed the severity of airflow obstruction. By contrast, in Phenotype 3, mortality distributed among all GOLD stages (Figure 3). Kaplan-Meier analysis of mortality between the 3 phenotypes is presented in Figure 4. Subjects in Phenotype 2 and 3 were at higher risk of mortality than subjects in Phenotype 1 (each comparison, P,0.0001; log-rank test), but no significant differenceCOPD Phenotypes at High Risk of MortalityTable 2. Description of the 527 COPD patients based on phenotypes identified by cluster analysis.Phenotype 1 n = 219 DATA USED 22948146 IN THE CLUSTER ANALYSIS Quantitative data Age, yrs. BMI, kg/m2 12926553 FEV1, predicted Dyspnoea, mMRC scale Clinical COPD Questionnaire, Total TGV, predicted DLCO, predicted Categorical data CT scan* Emphysema present, Alveolar destruction Absent ( ) Mild ( ) Moderate ( ) Severe ( ) Bronchial thickening Mild ( ) Moderate ( ) Severe ( ) Bronchiectasis, Comorbidities Ischemic heart disease, Stroke, Peripheral arterial disease*, Diabetes, Muscle weakness*, Osteoporosis, Anaemia, 14 0 10 9 18 8 5 57 33 9 14 52 35 8 5 48 62 [58?8] 25 [23?8] 80 [65?4] 0 [0?] 1.8 [1.0?.0] 126 [112?47] 74 [60?6]Phenotype 2 n =Phenotype 3 n =P value61 [57?6] 20 [18?2] 29 [21?7] 2 [1?] 6.8 [5.0?.0] 195 [177?20] 34 [25?9]72 [65?7] 26 [24?9] 44 [36?8] 2 [2?] 6.3 [4.5?.0] 139 [115?61] 47 [38?1],0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.,0.4 9 4319 32 27,0.36 45 1920 52 27,0.,0.17 2 11 11 47 3134 8 19 20 42 22,0.001 ,0.001 0.08 0.003 ,0.001 ,0.001 0.DATA NOT USED IN THE CLUSTER ANALYSIS Male sex, GOLD stage G 
I, ( of all GOLD stage I) G II, ( of all GOLD stage II) G III, ( of all GOLD stage III) G IV, ( of all GOLD stage IV) Source of recruitment NELSON cohort, ( NELSON) LEUVEN clinic, ( LEUVEN) Smoking, pack-year FEV1, L FVC, predicted FVC, L FEV1/FVC ratio RV, predicted TLC, predicted Raw, predicted 67 (95) 33 (19) 44 [34?0] 2.4 [1.9?.9] 105 [92?18] 4.0 [3.3?.6] 0.62 [0.53?.67] 128 [109?49] 106 100?18] 174 [140?23] 0 (0) 100 (27) 48 [33?6] 0.8 [0.6?.0] 72 [61?6] 2.6 [1.9?.2] 0.33 [0.27?.38] 227 [186?68] 128 [116?39] 274 [215?79] 3 (5) 97 (54) 48 [31?5] 1.25 [1.0?.6] 82 [69?4] 2.8 [2.3?.3] 0.44 [0.37?.55] 144 [113?74] 104 [91?14] 249 [198?17] ,0.001 ,0.001 0.89 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 50 (91) 39 (51) 9 (13) 2 (5) 0 (0) 8 (5) 37 (25) 55 (61) 5 (9) 36 (44) 44 (62) 15 (35) 80 66 80 0.007 ,0.COPD Phenotypes at High Risk of MortalityTable 2. Cont.Phenotype 1 n = 219 Sgaw, predicted Kco, predicted Mortality, n ( ) 68 [51?7] 86 [71?8] 1 (0.5 )Phenotype 2 n = 99 29 [22?0] 53 [45?2] 20 (20.6 )Phenotype 3 n = 209 44 [32?4] 70 [56?1] 29 (14.3 )P value,0.001 ,0.001 ,0.* missing data: Phenotype 1:67 ; Phenotype 2:1 , Phenotype 3:4 . P values correspond to comparisons between the 3 phenotypes using Kruskal-Wallis or Chi-square tests, as appropriate. doi:10.1371/journal.pone.0051048.twere very similar to those identified in the French study [11]. Because all subjects had extensive characterization, including complete lung function assessment and CT scan, our current data further improve the description of these phenotypes. GarciaAymerich et al. also performed a cluster analysis of 342 Spanish subjects hospitalized for the first time because of COPD exacerbation [12]. The authors described 3 phenotypes, including “a severe respiratory phenotype” and “a systemic COPD phenotype” [12], which were at high risk of s.
